Life Sciences

FDA Panel Will Examine Which COVID Strain Should Be the...

According to the FDA, the current dominant strain of COVID-19 should be a key fo...

Merck-Moderna’s Cancer Vaccine Collaboration Yields Pos...

In a follow-up study conducted on approximately 160 people, it was discovered th...

H7 Bird Flu Discovered on Fourth Poultry Farm in Australia

The government of Victoria in Australia announced that a highly virulent variant...

Soterios Achieves Phase 2 Success for Alopecia Cream as...

Soterios Pharma plans to proceed to phase 3 trials after its 1% Alopecia areata ...

New AstraZeneca-Derived Antibiotic Eliminates Deadly Ba...

Scientists have discovered a new antibiotic derived from AstraZeneca drugs that ...

Following a $34 million transaction, ADHD game creator ...

Akili Interactive, a firm that develops medical applications, announced earlier ...

Amgen’s Biosimilar of AstraZeneca’s Rare Blood Conditio...

The U.S. Food and Drug Administration has approved Bkemv by Amgen, the first bio...

Phase 3 Trial Results Show Datopotamab Deruxtecan Has P...

When compared to docetaxel, the TROPION-Lung01 Phase III trial indicated that da...

Vaccine Against Avian Influenza Proves to Be Effective ...

Globally, hundreds of millions of poultry have lost their lives to bird flu, or ...

Musk’s Neuralink Aiming to Enroll Three Patients in Bra...

According to the information on the clinical trials database maintained by the U...

J&J’s Antidepressant Shows Promising Sleep Results in T...

Johnson & Johnson developed seltorexant as an orexin-2 antagonist to prevent exc...

Nordson to Welcome Atrion into Its Medical and Fluid So...

In a bid to venture into the healthcare field from its domain in the industrial ...

Gerresheimer Increases the Capabilities of Medical Syst...

Gerresheimer, the maker of innovative systems and solutions and a partner to the...

AstraZeneca-Daiichi’s Enhertu Phase 3 Trial Demonstrate...

Daiichi Sankyo and AstraZeneca have applied to the FDA for their second-generati...

Neuren Phase 2 Study Shows Pitt Hopkins Syndrome Promise

Neuren Pharmaceuticals revealed key outcomes from its Phase 2 study of NNZ-2591 ...

Biogen Inks $1.15B Deal to Acquire HI-Bio

Biogen is investing $1.15 billion in Chris Viehbacher’s strategy to diversify th...